NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Oncovir is the commercial company that is providing the poly-ICLC for this trial. The autologous tumor lysate (ATL) - dendritic cell (DC) vaccine is being made in UCLA’s laboratory.

NWBio is not producing DCVax-L for this trial, through its CMOs (Cognate & Advent Bioservices). DCVax-L is the trademarked name for NWBio’s autologous tumor lysate (ATL) dendritic cell (DC) vaccine. ATL-DC is the generic name for DCVax-L.

I personally believe that UCLA, Merck & NWBio want to obscure & downplay the connections between the 3 entities, and hide in plain view, the combination trial for DCVax-L & Keytruda. This allows NWBio to focus on releasing TLD, and prevent Merck & NWBio from having to answer questions about the interest they may have in each other.